〔1〕中华人民共和国国家卫生健康委员会医政医管局. 原
发性肝癌诊疗规范(2019 年版)〔J〕. 中国实用外科
杂志, 2020, 40(2): 121-138.
〔2〕应倩, 汪媛. 肝癌流行现况和趋势分析〔J〕. 中国肿瘤,
2020, 29(3): 185-191.
〔3〕YU Y, WANG Y, XIAO X, et al. MiR-204 Inhibits
Hepatocellular Cancer Drug Resistance and Metastasis
through Targeting NUAK1〔J〕. Biochem Cell Biol,
2019, 97(5): 563-570.
〔4〕WANG Y T, YUAN B, CHEN H D, et al. Acquired
Resistance of Phosphatase and Tensin Homolog-
Deficient Cells to Poly(ADP-Ribose) Polymerase
Inhibitor and Ara-C Mediated by 53BP1 Loss and
SAMHD1 Overexpression〔J〕. Cancer Sci, 2018,
109(3): 821-831.
〔5〕NAIK A, AL-YAHYAEE A, ABDULLAH N, et al.
Neuropilin-1 Promotes the Oncogenic Tenascin-C/
Integrin 3 Pathway and Modulates Chemoresistance in
Breast Cancer Cells〔J〕. BMC Cancer, 2018, 18(1): 533.
〔6〕慕升君. 刺激响应型MSNs 异靶点共递送SF 和Tim-3
单抗用于肝细胞癌化学免疫联合治疗〔D〕. 济南: 山
东大学, 2018.
〔7〕刘俊勇, 夏盟恺, 彭芳. 美洲大蠊提取物逆转肝癌
耐药性的实验研究〔J〕. 中国生化药物杂志, 2015,
35(4): 19-23.
〔8〕李冉冉, 王兵, 胡胜, 等. 不同RNA 提取方法的效能
比较〔J〕. 刑事技术, 2018, 43(6): 431-435.
〔9〕OH J H, LEE J H, HAN D H, et al. Circadian Clock
Is Involved in Regulation of Hepatobiliary Transport
Mediated by Multidrug Resistance-Associated Protein
2〔J〕. J Pharm Sci, 2017, 106(9): 2491-2498. |